FOURKITES
16.11.2023 10:52:28 CET | Business Wire | Press release
FourKites today announces new additions to its senior leadership team to maximise customer value. Technology industry veteran Sean Fallon returns to FourKites as Chief Strategy Officer to drive strategy and support continued growth. Chief Product Officer Priya Rajagopalan takes on an expanded role that closely aligns customer operations and product development teams to maximise customer value. In addition, Mike DeAngelis (based in Denmark) joins as Head of International Solutions with a focus on ocean, having formerly worked at Maersk, WiseTech Global and project44.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116700075/en/
FourKites appoints new executives to accelerate customer-driven innovation (Graphic: Business Wire)
FourKites’ 1,200 customers represent some of the largest and most complex supply chains in the world, and the platform touches over 50% of the Fortune 500. As global supply chains continue to grow in complexity, customers’ need for visibility beyond transportation has accelerated, and now requires end-to-end solutions that provide visibility into inventory, yards, warehouses, stores and beyond.
Gartner reflected this challenge in its 2023 Critical Capabilities for Real-Time Transportation Visibility Platforms report, and recognised FourKites as the top-scoring solution for the world’s most complex supply chains, specifically calling out the company’s “modal coverage and extended capabilities.” In addition, FourKites continues to garner accolades for its industry-leading innovation, most recently in FreightWaves’ FreightTech 25, which recognises the most innovative and disruptive companies in the freight technology sector. FourKites is the only visibility provider named to this year’s list — and together with Amazon Freight and J.B. Hunt, it is one of only three companies to appear on every list since 2018.
To support FourKites’ aggressive innovation agenda to provide maximum visibility for its customers, FourKites has expanded the scope of Chief Product Officer Priya Rajagopalan’s role to encompass customer operations, product and R&D. A seasoned business leader with over two decades of experience in product management, marketing and strategy, Rajagopalan has led FourKites’ Product team since 2016. She helped to build FourKites’ culture of customer-driven innovation, as many of FourKites’ platform capabilities have been developed in close collaboration with customers such as Land O’Lakes, Coca-Cola, Kimberly-Clark, Walmart Canada and others.
In addition, FourKites announced the return of Sean Fallon as Chief Strategy Officer to manage operational execution. Fallon is a seasoned technology executive and advisor, with extensive experience in private equity and venture-backed companies. With a focus on advancing enterprise software and SaaS businesses, he has led businesses through strategic liquidity events and M&A, including the sale of BigMachines to Oracle in 2013. Fallon served as President at FourKites from 2017 to 2021.
FourKites has also appointed Mike DeAngelis as Head of Ocean, where he will drive strategy and innovation around FourKites’ ocean solutions. A proven industry leader, DeAngelis served as General Manager and Head of Product Management at Maersk, Senior VP of global carrier strategy at WiseTech Global, and was most recently Senior Director of Growth, Ocean, at project44.
“We are excited to announce these appointments at a time when customers are looking for more opportunities for digitisation than ever before,” said Mathew Elenjickal, FourKites founder and CEO. “These additions bring a tight connection between the voice of the customer and our high-velocity R&D team, which will yield accelerated opportunities for innovation and customer value.”
These appointments come at a time of continued company growth as customers increasingly seek solutions beyond transportation visibility. Over the last year, FourKites has achieved a 28% increase in customers; 37% growth in its carrier network; and nearly 30% growth in shipment volume, across more than 220 countries and territories. The company sets the pace of innovation in the supply chain visibility market — most recently with Inbound Visibility, Appointment Manager, Fin AI (FourKites Intelligence Network) and My Workspace — as FourKites continues to expand its capabilities beyond transportation to provide customers with real-time insights that expedite decision-making throughout their end-to-end supply chain operations.
About FourKites
Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116700075/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
